Roivant Sciences Ltd (ROIV) vs peers
$37.52
Latest weekly close · Market cap $27.0B
ROIV's P/E is not meaningful or is unavailable. Choose another measure to compare peers.
Peer group: Biotechnology. Updated .
| Stock | P/E | Own 5-year percentile |
|---|---|---|
| ROIVRoivant Sciences Ltd | n/m | n/m, not ranked |
| ABBVAbbVie | 82.1× | 77 |
| VRTXVertex Pharmaceuticals | 31.5× | 89 |
| AMGNAmgen | 28.6× | 80 |
| REGNRegeneron Pharmaceuticals | 20.2× | 68 |
| GILDGilead Sciences | n/m | n/m, not ranked |
| MRNAModerna | n/m | n/m, not ranked |
| NTRANatera Inc | n/m | n/m, not ranked |
| RVMDRevolution Medicines Inc | n/m | n/m, not ranked |
| Peer median | 30.0× |
How to read this comparison
Up to eight covered companies in the same industry, largest market value first.
P/E divides the share price by earnings per share over the last twelve months. The peer median leaves out ROIV and stocks without a reading.
Each percentile compares a stock with its own weekly readings over the last five years, so 20 means its P/E is above 20% of its own past readings. It needs at least 26 weeks of history. It is not a rank against the other stocks in this table.
Different growth rates, margins and financial risks can explain different multiples. Stocks without positive earnings have no reading.
ROIV versus the peer median
n/m
- ROIV
- n/m
- Peer median
- 30.0×
- Own 5-year median
- 2.1×